5 completed, 5 unknown, 2 recruiting, 1 active not recruiting. 13 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 5, Unknown 5, Recruiting 2, Active not recruiting 1 |
| Phase 1 | 1 | Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Antineoplastic Agents: new trials by email Literature Review of Antineoplastic Agents trials Research Report on Antineoplastic Agents
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer Befotertinib combined Bevacizumab, Befotertinib combined platinum-based double chemotherapy - EGFR, Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Peng Zhang | 60 | 2024-11-07 | 2025-01-06 |
| Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma Nivolumab Injection [Opdivo] - Neoplasms, Carcinoma, Squamous | Phase 2 | Recruiting | The First Affiliated Hospital of Guangzhou Medical University | 25 | 2023-08-15 | 2026-11-09 |
| Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery Hepatic arterial infusion chemotherapy, Folfox Protocol, Donafenib - Carcinoma, Carcinoma, Hepatocellular | Phase 2 | Completed | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 30 | 2021-12-27 | 2026-06-30 |
| Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma Anlotinib, Cisplatin, Carboplatin - Urothelial Carcinoma, Anlotinib | Phase 2 | Unknown | Tianjin Medical University Second Hospital | 53 | 2021-10-01 | 2021-09-01 |
| Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer Drug: Anlotinib, Drug: Carboplatin/Paclitaxel - Ovarian Neoplasms, Fallopian Tube Neoplasms | Phase 2 | Active not recruiting | Wenjun Cheng | 56 | 2021-08-24 | 2024-07-03 |
| Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01) tislelizumab and BCG - Urinary Bladder Neoplasms, Urologic Neoplasms | Phase 1 / Phase 2 | Unknown | RenJi Hospital | 6 | 2021-06-01 | 2021-06-11 |
| Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer Niraparib, Bevacizumab - Ovarian Neoplasms, Fallopian Tube Neoplasms | Phase 2 | Unknown | Xiaoxiang Chen | 32 | 2020-11-06 | 2020-11-10 |
| Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Anlotinib, Olaparib - Ovarian Cancer, Ovarian and Fallopian Tube Cysts and Neoplasms | Phase 2 | Unknown | Xiaoxiang Chen | 68 | 2020-10-28 | 2020-10-30 |
| TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC TACE combined with sorafenib and PD-1 mAb - Hepatocellular Carcinoma, Liver Neoplasms | Phase 2 | Completed | Sichuan Cancer Hospital and Research Institute | 27 | 2020-09-14 | 2024-06-25 |
| Anlotinib in Metastatic HER2 Negative Breast Cancer Anlotinib Hydrochloride - Breast Neoplasm, Antineoplastic Agents | Phase 2 | Completed | Peng Yuan | 26 | 2018-07-12 | 2020-07-29 |
| Avelumab in Refractory Testicular Germ Cell Cancer. Avelumab - Testicular Neoplasms, Neoplasms, Germ Cell and Embryonal | Phase 2 | Completed | National Cancer Institute, Slovakia | 8 | 2017-11-15 | 2019-03-05 |
| Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer. Palonosetron, Ondansetron - Breast Neoplasm, Antineoplastic Agents | Phase 2 / Phase 3 | Unknown | Instituto Nacional de Cancerologia de Mexico | 560 | 2015-11-05 | 2018-07-30 |
| Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy STI571 (Glivec®) - Prostatic Neoplasm, Genital Neoplasms, Male | Phase 2 | Completed | Novartis Pharmaceuticals | 51 | 2003-06-01 | 2017-06-01 |
Urogenital Neoplasms (5) · Carcinoma (4) · Neoplasms (4) · Carcinoma, Ovarian Epithelial (3) · Genital Diseases, Female (3) · Genital Neoplasms, Female (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Glandular and Epithelial (3) · Ovarian Diseases (3) · Ovarian Neoplasms (3) · Adnexal Diseases (2) · Breast Neoplasms (2) · Carcinoma, Hepatocellular (2) · Digestive System Neoplasms (2)
Neoplasms by Site (10) · Neoplasms (9) · Urogenital Diseases (7) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Male Urogenital Diseases (6) · Genital Diseases (5) · Neoplasms by Histologic Type (5) · Neoplasms, Glandular and Epithelial (4) · Carcinoma (3) · Endocrine Gland Neoplasms (3) · Adenocarcinoma (2) · Breast Diseases (2) · Digestive System Diseases (2) · Endocrine System Diseases (2)
anlotinib (4) · Carboplatin (2) · Bevacizumab (1) · CP protocol (1) · Cisplatin (1) · Fluorouracil (1) · Folfox protocol (1) · Gemcitabine (1) · Imatinib Mesylate (1) · Leucovorin (1) · Nivolumab (1) · Ondansetron (1) · Oxaliplatin (1) · Paclitaxel (1) · Palonosetron (1)
Xiaoxiang Chen (2) · Instituto Nacional de Cancerologia de Mexico (1) · National Cancer Institute, Slovakia (1) · Novartis Pharmaceuticals (1) · Peng Yuan (1) · Peng Zhang (1) · RenJi Hospital (1) · Sichuan Cancer Hospital and Research Institute (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · The First Affiliated Hospital of Guangzhou Medical University (1) · Tianjin Medical University Second Hospital (1) · Wenjun Cheng (1)
China (10) · Germany (1) · Mexico (1) · Slovakia (1)
Xiaoxiang Chen, MD,PhD (2) · Claudia H Arce Salinas, MD (1) · Lei Zhang, PHD (1) · Michal Mego, prof (1) · Peng Yuan (1) · Shuben Li, PhD (1) · Wenjun Cheng, MD,PhD (1) · Yuanjie Niu, MD,PhD (1)
PMID 11226762, PMID 12686700, PMID 12697943, PMID 1352024, PMID 15139073, PMID 16766588, PMID 17187507, PMID 17530482, PMID 18525044, PMID 19037667, PMID 20972805, PMID 21533811, PMID 22488022, PMID 23358260, PMID 24761161, PMID 25012726, PMID 25106522, PMID 3281702, PMID 3544842, PMID 6681766, PMID 9789602